Maccura Biotechnology Co Stock Revenue
| 300463 Stock | 13.84 0.72 4.95% |
Maccura Biotechnology Co fundamentals help investors to digest information that contributes to Maccura Biotechnology's financial success or failures. It also enables traders to predict the movement of Maccura Stock. The fundamental analysis module provides a way to measure Maccura Biotechnology's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Maccura Biotechnology stock.
| Last Reported | Projected for Next Year | ||
| Total Revenue | 2.9 B | 2.5 B |
Maccura | Revenue |
Maccura Biotechnology Co Company Revenue Analysis
Maccura Biotechnology's Revenue is income that a firm generates from business activities such us rendering services or selling goods to customers. It is a crucial part of a business and an essential item when evaluating a company's financial statements. Revenues from a firm's primary business operations can be reported on the income statement as sales revenue, net sales, or simply sales, depending on the industry in which a given company operates.
Current Maccura Biotechnology Revenue | 2.9 B |
Most of Maccura Biotechnology's fundamental indicators, such as Revenue, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Maccura Biotechnology Co is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Historical and Projected quarterly revenue of Maccura
Projected quarterly revenue analysis of Maccura Biotechnology provides investors and stakeholders with an insight into the company's performance and growth prospects. When actual revenues of Maccura Biotechnology match or exceed analyst estimates, it positively influences investor confidence and market perception, often leading to a rise in Maccura Biotechnology's stock price.
Revenue is typically recorded when cash or cash equivalents are exchanged for services or goods and can include products or services discounts, promotions, as well as early payments on invoices or services rendered in advance.
| Competition |
Maccura Total Revenue
Total Revenue |
|
Based on the latest financial disclosure, Maccura Biotechnology Co reported 2.9 B of revenue. This is much higher than that of the Life Sciences Tools & Services sector and significantly higher than that of the Health Care industry. The revenue for all China stocks is notably lower than that of the firm.
Maccura Revenue Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Maccura Biotechnology's direct or indirect competition against its Revenue to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Maccura Biotechnology could also be used in its relative valuation, which is a method of valuing Maccura Biotechnology by comparing valuation metrics of similar companies.Maccura Biotechnology is currently under evaluation in revenue category among its peers.
Maccura Fundamentals
| Return On Equity | 0.0485 | ||||
| Return On Asset | 0.0219 | ||||
| Profit Margin | 0.12 % | ||||
| Operating Margin | 0.17 % | ||||
| Current Valuation | 8.75 B | ||||
| Shares Outstanding | 612.47 M | ||||
| Shares Owned By Insiders | 40.27 % | ||||
| Shares Owned By Institutions | 4.76 % | ||||
| Price To Book | 1.37 X | ||||
| Price To Sales | 3.22 X | ||||
| Revenue | 2.9 B | ||||
| Gross Profit | 1.96 B | ||||
| EBITDA | 613.34 M | ||||
| Net Income | 312.62 M | ||||
| Total Debt | 144.65 M | ||||
| Book Value Per Share | 10.79 X | ||||
| Cash Flow From Operations | 901.51 M | ||||
| Earnings Per Share | 0.53 X | ||||
| Target Price | 13.79 | ||||
| Number Of Employees | 3.36 K | ||||
| Beta | 0.38 | ||||
| Market Capitalization | 8.8 B | ||||
| Total Asset | 8.12 B | ||||
| Retained Earnings | 3.84 B | ||||
| Working Capital | 3.1 B | ||||
| Annual Yield | 0.01 % | ||||
| Net Asset | 8.12 B | ||||
| Last Dividend Paid | 0.15 |
About Maccura Biotechnology Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Maccura Biotechnology Co's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Maccura Biotechnology using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Maccura Biotechnology Co based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Other Information on Investing in Maccura Stock
Maccura Biotechnology financial ratios help investors to determine whether Maccura Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Maccura with respect to the benefits of owning Maccura Biotechnology security.